Richard E. Kanner - Concepedia

Author

Richard E. Kanner

Also Known As

Bleecker, Eugene R., Cooper, Christopher B, Couper, David, Fernando J. Martinez, Foreman, Marilyn G., Han, Meilan K., Hoffman, Eric A., Kanner, Richard E, Martinez, Carlos H, Martinez, Fernando J

243

Publications

13.5K

Citations

H-Index

131

Concepts

All Affiliations

University of Utah Johns Hopkins University University of California, Los Angeles University of North Carolina at Chapel Hill University of California, San Francisco

About

Richard E. Kanner is an author at University of Utah specializing in medicine, pulmonary disease, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	44	4.5K
2	Public Health	17	21	3.3K
3	Engineering	3	3	888
4	Health Sciences	2	2	168
5	Education	1	1	120

Richard E. Kanner

111

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality Nicholas R. Anthonisen, M.A. Skeans, Robert A. Wise, Annals of Internal Medicine	2005	1.2K
Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function Prescott G. Woodruff, R. Graham Barr, Eugene R. Bleecker, New England Journal of Medicine	2016	673
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Nicholas R. Anthonisen, John E. Connett, James P. Kiley, PubMed	1994	665
Heart rate variability associated with particulate air pollution C. Arden Pope, Richard L. Verrier, Eric G. Lovett, American Heart Journal EngineeringAtmospheric ScienceEnvironmental HealthAir QualityAir Pollution	1999	599
Lower Respiratory Illnesses Promote FEV <sub>1</sub> Decline in Current Smokers But Not Ex-Smokers with Mild Chronic Obstructive Pulmonary Disease Richard E. Kanner, Nicholas R. Anthonisen, John E. Connett American Journal of Respiratory and Critical Care Medicine	2001	587
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial DP Tashkin, Richard E. Kanner, William C. Bailey, The Lancet Tobacco CessationTobacco ControlTobacco UseRandomised TrialPublic Health	2001	416
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1 David Couper, Lisa M. LaVange, MeiLan K. Han, Thorax Table 1EpidemiologyPulmonary CareDisease ProgressionCopd Participants	2013	390
Airway Mucin Concentration as a Marker of Chronic Bronchitis Mehmet Kesımer, Amina A. Ford, Agathe Ceppe, New England Journal of Medicine	2017	359
Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Donald P. Tashkin, Murray D. Altose, John E. Connett, American Journal of Respiratory and Critical Care Medicine AsthmaTobacco ControlAdvanced Lung DiseaseLung InflammationAirway Reactivity	1996	314
Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort Annette T. Hastie, Fernando J. Martínez, Jeffrey L. Curtis, The Lancet Respiratory Medicine EpidemiologyBlood Eosinophil ConcentrationsAdvanced Lung DiseaseMedicineClinical Epidemiology	2017	307

Page 1